Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials

BACKGROUND: Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have different toxicity profile. There are limited data comparing the side effects of abiraterone and enzalutamide. We performed a meta-analysis of randomized con...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Moreira, Raphael B., Debiasi, Marcio, Francini, Edoardo, Nuzzo, Pier V., Velasco, Guillermo De, Maluf, Fernando C., Fay, Andre P., Bellmunt, Joaquim, Choueiri, Toni K., Schutz, Fabio A.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5663621/
https://ncbi.nlm.nih.gov/pubmed/29137449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20028
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items